Rocket Pharmaceuticals (RCKT) Stock Forecast & Price Target

$3.07 +0.30 (+10.83%)

Closing price 06/6/2025 04:00 PM Eastern

Extended Trading

$3.06 -0.01 (-0.49%)

As of 06/6/2025 07:50 PM Eastern

Rocket Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 17 Analyst Ratings

Sell
1

Hold
8

Buy
8

Based on 17 Wall Street analysts who have issued ratings for Rocket Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Hold." Out of the 17 analysts, 1 has given a sell rating, 8 have given a hold rating, and 8 have given a buy rating for RCKT.

Consensus Price Target

$19.57
537.51% Upside

According to the 17 analysts' twelve-month price targets for Rocket Pharmaceuticals, the average price target is $19.57. The highest price target for RCKT is $44.00, while the lowest price target for RCKT is $5.00. The average price target represents a forecasted upside of 537.51% from the current price of $3.07.

Get the Latest News and Ratings for RCKT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Rocket Pharmaceuticals and its competitors.

RCKT Analyst Ratings Over Time

Type	Current Forecast 6/7/24 to 6/7/25	1 Month Ago 5/8/24 to 5/8/25	3 Months Ago 3/9/24 to 3/9/25	1 Year Ago 6/8/23 to 6/7/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	11 Buy rating(s)	10 Buy rating(s)	9 Buy rating(s)
Hold	8 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)
Sell	1 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$19.57	$43.00	$42.30	$52.13
Forecasted Upside	537.51% Upside	510.80% Upside	382.33% Upside	129.83% Upside
Consensus Rating	Hold	Moderate Buy	Moderate Buy	Moderate Buy

RCKT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

RCKT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Rocket Pharmaceuticals Stock vs. The Competition

Type	Rocket Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.41	2.81	2.54
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	537.51% Upside	5,716.31% Upside	13.73% Upside
News Sentiment Rating	Neutral News See Recent RCKT News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
6/3/2025	Canaccord Genuity Group 2 of 5 stars	Whitney Ijem Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$34.00 ➝ $11.00	+297.11%
5/30/2025	Evercore ISI 2 of 5 stars	G. Clark-Gartner Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ In-Line	$5.00	+102.02%
5/28/2025	UBS Group 3 of 5 stars		Reiterated Rating	Buy ➝ Buy
5/28/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Neutral
5/28/2025	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Greg Harrison Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$32.00 ➝ $9.00	+259.28%
5/28/2025	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	K. Biliouris Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$30.00 ➝ $8.00	+224.54%
5/28/2025	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Greg Harrison Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Sector Outperform ➝ Sector Outperform	$51.00 ➝ $19.00	+690.02%
5/28/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Law Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Sell
5/28/2025	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Mani Foroohar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$37.00 ➝ $8.00	+243.35%
5/28/2025	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Equal Weight	$7.00	+200.43%
Get the Latest News and Ratings for RCKT and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
5/28/2025	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Geulah Livshits Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$46.00 ➝ $17.00	+629.61%
5/28/2025	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Andrew Tsai Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/27/2025	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Foroohar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/27/2025	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Van. Buren Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/27/2025	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Gil Blum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$42.00	+1,596.96%
5/16/2025	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Josh Schimmer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$20.00 ➝ $30.00	+361.75%
5/16/2025	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Y. Zhong Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$32.00 ➝ $32.00	+390.05%
6/3/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
12/26/2023	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Jubinville Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
9/13/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$48.00	+124.30%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 02:58 PM ET.

RCKT Forecast - Frequently Asked Questions

: According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for Rocket Pharmaceuticals is $19.57, with a high forecast of $44.00 and a low forecast of $5.00.
: 17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last year. There is currently 1 sell rating, 8 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" RCKT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RCKT, but not buy additional shares or sell existing shares.
: According to analysts, Rocket Pharmaceuticals's stock has a predicted upside of 537.51% based on their 12-month stock forecasts.
: Over the previous 90 days, Rocket Pharmaceuticals's stock had 4 downgrades by analysts.
: Rocket Pharmaceuticals has been rated by research analysts at Bank of America, BMO Capital Markets, Canaccord Genuity Group, Cantor Fitzgerald, Chardan Capital, Evercore ISI, Jefferies Financial Group, JPMorgan Chase & Co., Leerink Partners, Leerink Partnrs, Morgan Stanley, Needham & Company LLC, Scotiabank, TD Cowen, The Goldman Sachs Group, UBS Group, and Wedbush in the past 90 days.
: Analysts like Rocket Pharmaceuticals less than other "medical" companies. The consensus rating for Rocket Pharmaceuticals is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how RCKT compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:RCKT) was last updated on 6/7/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rocket Pharmaceuticals (RCKT) Stock Forecast & Price Target